Epoch Investment Partners Inc. Has $25.42 Million Holdings in Bruker Co. (NASDAQ:BRKR)

Epoch Investment Partners Inc. lessened its holdings in shares of Bruker Co. (NASDAQ:BRKR) by 1.2% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 322,460 shares of the medical research company’s stock after selling 3,981 shares during the period. Epoch Investment Partners Inc. owned 0.22% of Bruker worth $25,423,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in BRKR. Zions Bancorporation N.A. bought a new stake in Bruker during the 1st quarter worth approximately $26,000. Altshuler Shaham Ltd bought a new position in Bruker during the fourth quarter worth about $27,000. Belpointe Asset Management LLC acquired a new position in Bruker during the fourth quarter worth approximately $28,000. Orion Capital Management LLC bought a new stake in Bruker in the first quarter valued at approximately $28,000. Finally, CoreCap Advisors LLC acquired a new stake in shares of Bruker in the fourth quarter valued at approximately $42,000. Institutional investors and hedge funds own 79.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on Bruker in a report on Thursday, August 17th. They set a “buy” rating on the stock. One analyst has rated the stock with a sell rating and three have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $84.50.

Bruker Price Performance

Shares of Bruker stock traded down $0.50 on Wednesday, reaching $63.45. 38,678 shares of the stock were exchanged, compared to its average volume of 806,916. The firm’s 50 day moving average is $69.12 and its 200-day moving average is $73.19. The firm has a market cap of $9.32 billion, a PE ratio of 29.61, a P/E/G ratio of 1.39 and a beta of 1.13. Bruker Co. has a one year low of $48.42 and a one year high of $84.84. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.21 and a current ratio of 2.08.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, August 3rd. The medical research company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.02. Bruker had a return on equity of 33.24% and a net margin of 11.76%. The firm had revenue of $681.90 million during the quarter, compared to the consensus estimate of $647.82 million. During the same period last year, the business posted $0.45 EPS. The business’s revenue was up 15.9% compared to the same quarter last year. As a group, analysts anticipate that Bruker Co. will post 2.57 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, September 1st will be paid a dividend of $0.05 per share. The ex-dividend date of this dividend is Thursday, August 31st. This represents a $0.20 dividend on an annualized basis and a yield of 0.32%. Bruker’s dividend payout ratio is currently 9.26%.

Insider Buying and Selling at Bruker

In related news, CFO Gerald N. Herman sold 14,242 shares of the company’s stock in a transaction on Friday, June 16th. The shares were sold at an average price of $75.42, for a total value of $1,074,131.64. Following the completion of the transaction, the chief financial officer now owns 36,462 shares of the company’s stock, valued at approximately $2,749,964.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Bruker news, CEO Frank H. Laukien sold 37,947 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $64.81, for a total value of $2,459,345.07. Following the completion of the sale, the chief executive officer now owns 38,217,344 shares of the company’s stock, valued at $2,476,866,064.64. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Gerald N. Herman sold 14,242 shares of the company’s stock in a transaction dated Friday, June 16th. The shares were sold at an average price of $75.42, for a total transaction of $1,074,131.64. Following the transaction, the chief financial officer now owns 36,462 shares in the company, valued at approximately $2,749,964.04. The disclosure for this sale can be found here. Company insiders own 28.20% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies.